{"id":2394,"date":"2013-11-01T01:12:34","date_gmt":"2013-11-01T01:12:34","guid":{"rendered":"https:\/\/www.videoshelf.com\/blog\/?p=2394"},"modified":"2013-11-01T16:02:22","modified_gmt":"2013-11-01T16:02:22","slug":"fda-approved-botox-injections-for-crows-feet-learn-how-to-inject-botox-with-botox-training-video-dvd","status":"publish","type":"post","link":"https:\/\/www.videoshelf.com\/blog\/fda-approved-botox-injections-for-crows-feet-learn-how-to-inject-botox-with-botox-training-video-dvd\/","title":{"rendered":"FDA just approved Botox\u00ae Injections for Crow’s Feet – Learn How To Inject Botox"},"content":{"rendered":"

On Sept. 11, 2013, the U.S. Food and Drug Administration (FDA) approved BOTOX\u00ae<\/sup> Cosmetic to improve the appearance of crow\u2019s feet lines. The FDA regulates the approval of prescription drugs in the United States.<\/p>\n

\"Learn<\/a>In 2002, The FDA approved Botox Cosmetic for the temporary improvement of glabellar lines (wrinkles between the eyebrows, known as frown lines), in adults. Botox Cosmetic works by keeping muscles from contracting so wrinkles are less prominent.<\/p>\n

Now there is a new FDA approved use for Botox Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines, known as crow\u2019s feet<\/i>, in adults.<\/p>\n

\"Botox<\/a>BOTOX\u00ae<\/sup> Cosmetic is the only FDA approved drug treatment option for lateral canthal lines.<\/p>\n

Botox Cosmetic is administered via intramuscular injections.<\/p>\n

Plastic Surgeons have been doing the lateral canthal line procedure for years without FDA approval because they are allowed to prescribe the cosmetic procedure off label. Allergan, Inc., based in Irvine, California is the producer of registered brand Botox\u00ae.<\/p>\n

“Botox Cosmetic\u2019s safety and effectiveness for treating lateral canthal lines were established in two clinical efficacy and safety studies. The studies enrolled 833 adult participants with moderate to severe lateral canthal lines who were randomly assigned to receive Botox or placebo. Results showed that those treated with Botox had greater improvement compared to placebo in the appearance of lateral canthal lines.”, according to the FDA.<\/p>\n

\u201cThis additional indication will provide people with a new FDA approved treatment option for those seeking a smoother appearance by temporarily minimizing the appearance of crow\u2019s feet at the sides of the eyes,\u201d said Susan Walker, M.D., director of the Division of Dermatology and Dental Products in the FDA\u2019s Center for Drug Evaluation and Research.<\/p>\n

Treatment for both frown lines and crow\u2019s feet can be given at the same time.<\/p>\n

When a small amount of BOTOX\u00ae<\/sup> is injected into a muscle, it blocks nerve signals that tell the muscles to contract. BOTOX\u00ae<\/sup> blocks nerve signals because it binds to the nerves that lead to the muscle and prevent the release of acetylcholine, a neurotransmitter that activates muscle contractions. This causes a temporary paralysis in muscle activity.<\/p>\n

The BOTOX\u00ae <\/sup>toxin (onabotulinumtoxinA), also called botulinum toxin type A, is made from Clostridium botulinum<\/em> bacteria, which is the same bacteria that causes botulism, a life-threatening type of food poisoning.<\/p>\n

BOTOX\u00ae<\/sup> is made by Allergan, Inc. Allergan offers a number of products, including: BOTOX\u00ae<\/sup> (onabotulinumtoxinA), BOTOX\u00ae<\/sup> Cosmetic (onabotulinumtoxinA) and the JUV\u00c9DERM\u00ae<\/sup> family of dermal fillers.<\/p>\n

Allergan estimates that worldwide, approximately 35 million vials of their botulinum toxin type A products have been distributed over the past 21 years (1990-2012).<\/p>\n

“With approximately 65 randomised, placebo-controlled clinical trials involving approximately 15,000 patients and, with more than 2,500 articles in scientific and medical journals, Allergan’s neurotoxin is one of the most widely researched medicines in the world”, says Allergan.<\/p>\n

The global botox market is forecast to reach $2.9 billion by 2018, with a year-over-year growth rate of 14%. The entire global market for facial aesthetics is forecast to reach $4.7 billion in 2018, of which the US is expected to contribute over $2 billion, according to a new market research report by Companies & Markets.<\/p>\n

\"Dolores<\/a>Dolores Kent, M.D., F.A.C.O.G. is a board-certified Harvard Medical School graduate, Cosmetic Surgeon and Gynecologist, with over 20 years of experience.<\/p>\n

She is one of the pioneers in Botox\u00ae injection techniques for crow’s feet. Having an office in Hollywood, California has kept her ahead of the curve with cosmetic procedures.<\/p>\n

Dolores Kent, M.D.,\u00a0F.A.C.O.G., is a Harvard Medical School Graduate and an experienced Beverly Hills-based cosmetic surgeon with over 20 years of experience. She provides Botox\u00ae training for nurses, surgeons, and dermatologists through online training videos and DVDs at Aesthetic VideoSource<\/a>.<\/p>\n

Dolores Kent, M.D., demonstrates how to inject\u00a0Botox\u00ae for common cosmetic procedures, including:<\/strong><\/p>\n